PT-141 raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2026-02-18. Anything still debated is marked as such rather than presented as settled.
Bremelanotide is a synthetic cyclic heptapeptide developed under the research code PT-141. The code reflects its position in an internal compound series rather than a chemical classification, and the name bremelanotide was later adopted for regulatory filings. Structurally it belongs to the melanocortin peptide family and shares a core sequence motif with alpha-melanocyte-stimulating hormone. The compound is supplied as an acetate salt in aqueous solution for injection. In reference literature it is indexed under both the code and the generic name, a dual listing that can complicate database searches.
Early work on melanocortin analogs in the 1980s and 1990s produced peptides intended to influence pigmentation and appetite. One of these, melanotan II, was observed to affect sexual desire as an incidental finding in self-administration reports. Researchers then pursued analogs with altered receptor selectivity and improved handling characteristics, and PT-141 emerged from that program in the late 1990s. The development path moved from dermatology and metabolism toward a central nervous system application, a shift that shaped both trial designs and the eventual label.
Regulatory review of bremelanotide concluded in 2019 with approval in the United States for a defined indication in premenopausal women. The reviewed formulation is a single-use prefilled autoinjector given subcutaneously, and its label carries cardiovascular monitoring language tied to blood pressure changes recorded during trials. Availability outside the approving jurisdiction varies, and in several countries the compound remains unapproved or is handled as a prescription-only item. Compounded and research-grade material also circulates, and it differs from the reviewed product in purity, characterization, and chain of custody.
Melanocortin receptors form a family of five G-protein-coupled proteins, labelled MC1R through MC5R, that respond to peptides derived from pro-opiomelanocortin. Alpha-melanocyte-stimulating hormone and adrenocorticotropic hormone are the best-known endogenous ligands. The receptors are distributed differently across tissues, so a single agonist can produce effects in the brain, skin, adrenal gland and vasculature. This distribution explains why one peptide can influence both pigmentation and motivated behaviour.
Bremelanotide is a cyclic heptapeptide that binds several melanocortin receptors rather than one. In vitro assays report agonist activity at MC1R, MC3R, MC4R and MC5R, with MC4R generally treated as the subtype most relevant to sexual effects. MC4R is expressed in hypothalamic nuclei involved in appetite, energy balance and motivated behaviour, which provides a plausible route for central action. Selective MC4R agonists studied in animals produce comparable behavioural changes, supporting that interpretation.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C50H68N14O10 | Cyclic heptapeptide core |
| Molecular weight | 1025.2 g/mol | Calculated for the free base |
| CAS registry number | 189691-06-3 | Free base; the acetate salt has a separate entry |
| Solubility class | Water-soluble | Freely soluble in aqueous media near neutral pH |
| Typical storage | 2 to 8 °C | Protect from light; avoid repeated freeze-thaw cycles |
Bremelanotide acts as an agonist at melanocortin receptors, a family of five G-protein-coupled receptors labeled MC1 through MC5. Binding studies indicate activity at several of these subtypes rather than strict selectivity for one. Signalling proceeds mainly through Gs-mediated activation of adenylyl cyclase, raising intracellular cyclic AMP. The MC4 receptor, expressed in hypothalamic and limbic circuits, is widely regarded as the subtype most relevant to sexual response. Because the molecule is not subtype-selective, effects at other melanocortin receptors are expected and are used to explain some observed side effects.
The peptide contains seven amino acids arranged in a ring, closed by a lactam bridge between a side-chain acid and an amine. This cyclic constraint holds the backbone in a defined conformation and increases resistance to enzymatic breakdown relative to linear analogs. N-terminal acetylation and a C-terminal amide further protect the molecule from exopeptidases. The result is a compound with a comparatively long circulation time for a small peptide. Structural modification of the bridge alters receptor affinity, which is one reason analogs in this family differ in their subtype preferences.
Bremelanotide is a synthetic cyclic heptapeptide that acts on a family of G-protein-coupled receptors. It was designed as a structural analogue of alpha-melanocyte-stimulating hormone, the endogenous peptide associated with pigmentation and several central signalling pathways. A lactam bridge constrains the ring and slows enzymatic breakdown, which distinguishes it from the linear parent molecule. Research interest moved over time from pigment biology toward central nervous system effects, particularly circuits connected to sexual desire. Parenteral delivery is used because oral bioavailability is poor.
Early clinical work used an intranasal formulation, and later programmes switched to subcutaneous delivery for more consistent absorption. A subcutaneous product received regulatory approval in the United States in 2019 for premenopausal women with acquired, generalised hypoactive sexual desire disorder. Approval followed phase 3 trials in which active treatment separated from placebo on desire and distress measures, though the average difference was modest. Labeling carries a caution about transient blood pressure elevation, so cardiovascular history is assessed before prescribing. Questions about durability of benefit beyond several months remain open.
Melanocortin receptors form a family of five G-protein-coupled receptors designated MC1 through MC5. Bremelanotide binds most strongly at MC4R and MC1R, with weaker activity reported at MC3R and MC5R. MC4R is expressed in hypothalamic nuclei that coordinate energy balance and aspects of sexual behaviour. The prevailing interpretation is that central MC4R activation, rather than peripheral vascular effects alone, drives the reported changes in desire. This account remains partly inferential, since direct receptor-level measurement in living humans is not practical.
After subcutaneous administration, plasma concentrations rise within roughly thirty minutes and the elimination half-life is short, on the order of two to three hours. Reported physiological responses include transient increases in blood pressure and nausea, which tended to diminish with repeated dosing in trial settings. Because the peptide clears quickly, effects are not expected to persist long after a dose. Absorption from non-injected routes is poorly characterised, and nasal delivery produced variable plasma levels in older work.
An ion-exchange resin such as chelex 100, which contains chelating ligands bound to a polymer, can be used in water softeners and in chromatographic separation techniques. In solvent extraction the formation of electrically neutral complexes allows cations to be extracted into organic solvents. For example, in nuclear fuel reprocessing uranium(VI) and plutonium(VI) are extracted into kerosene as the complexes [MO2(TBP)2(NO3)2] (TBP = tri-n-butyl phosphate). In phase-transfer catalysis, a substance which is insoluble in an organic solvent can be made soluble by addition of a suitable ligand. For example, potassium permanganate oxidations can be achieved by adding a catalytic quantity of a crown ether and a small amount of organic solvent to the aqueous reaction mixture, so that the oxidation reaction occurs in the organic phase. In all these examples, the ligand is chosen on the basis of the stability constants of the complexes formed. For example, TBP is used in nuclear fuel reprocessing because (among other reasons) it forms a complex strong enough for solvent extraction to take place, but weak enough that the complex can be destroyed by nitric acid to recover the uranyl cation as nitrato complexes, such as [UO2(NO3)4]2− back in the aqueous phase.
=== Molecular Separations === The well-defined pore structure of organic cages enables selective molecular separations. Molecular cages can discriminate between molecules based on size, shape, and chemical affinity. Gas separation represents a major application, where cages are incorporated into mixed-matrix membranes for selective gas transport. Studies have demonstrated effective separation of CO2/N2, CO2/CH4, and other industrially relevant gas mixtures. The uniform pore size and chemical environment ensure consistent separation performance. In liquid-phase separations, organic cages show promise for challenging molecular separations. Their solution processability enables incorporation into chromatographic stationary phases. The intrinsic chirality of some cage structures allows for enantioselective separations of racemic mixtures, achieving high separation factors for pharmaceutical and fine chemical applications.
Heart rate reduction, i.e., decrease of the resting heart rate (negative chronotropic effect) and reduction of excessive elevations resulting from exercise or stress. Reduction of the force of contraction, i.e., decrease in contractility (negative inotropic effect), which lessens how hard each heartbeat contracts. Decrease in cardiac output, i.e., decrease in both heart rate and contractility within myocardium cells, where β1 is predominantly located, overall blood output per minute lowers called cardiac output/dysfunction, allowing decreased demands placed onto impaired hearts, reducing oxygen demand-supply mismatch. Lowering of blood pressure. Antiarrhythmic effects, such as supraventricular tachycardia prevention. Metoprolol also prevents electrical wave propagation. Metoprolol inhibits CYP2J2.
Sources: en.wikipedia.org
Chancellor Rachel Reeves conducts a spending review in which she limits winter fuel payments to pensioners receiving pension credit (affecting around 10 million people), and announces the cancellation of several infrastructure projects. Reeves argues she has had to make "necessary and urgent decisions" because of an "unfunded" and "undisclosed" overspending of £21.9bn by the previous government. The shadow chancellor, Jeremy Hunt, disagrees with Reeves, saying that when his party was in power there were no hidden overspends and that the government had been open about public finances. Hunt says Reeves misled the country knowing "taxes will have to go up, and she chose not to tell us". He predicts that her first Budget will be the "biggest betrayal in history by a new chancellor". The new Labour government scraps the controversial proposed Stonehenge road tunnel. 2024 Summer Olympics: The first gold medal for Team GB is won by Laura Collett in the final round of show jumping. Tom Pidcock wins a second in mountain biking later in the day. A judge issues an arrest warrant for Tommy Robinson after he left the UK via Eurotunnel on the eve of a major court case against him. Former BBC newsreader Huw Edwards is charged with making indecent images of children. The High Court rules that the previous government's use of emergency legislation to ban puberty blockers is lawful. 30 July 2024 Southport stabbing: The three young girls killed in the attack are named as Bebe King, aged 6; Elsie Dot Stancombe, aged 7; and Alice Dasilva Aguiar, aged 9.
A glycoprotein is a compound containing carbohydrate (or glycan) covalently linked to protein. The carbohydrate may be in the form of a monosaccharide, disaccharide(s), oligosaccharide(s), polysaccharide(s), or their derivatives (e.g. sulfo- or phospho-substituted). One, a few, or many carbohydrate units may be present. Proteoglycans are a subclass of glycoproteins in which the carbohydrate units are polysaccharides that contain amino sugars. Such polysaccharides are also known as glycosaminoglycans.
In November 2022, Cerebras announced a partnership with Cirrascale Cloud Services to provide a flat-rate "pay-per-model" compute time for its Cerebras AI Model Studio. In November 2022, the National Energy Technology Laboratory (NETL) set milestones using Cerebras products. In November 2022, Argonne National Laboratory won the 2022 Gordon Bell Special Prize for COVID-19 research by using the CS-2 as well as products from Nvidia and Hewlett-Packard to transform large language models to analyze and predict variants of SARS-CoV-2. In July 2023, G42 agreed to pay around $100 million to purchase the first of potentially nine supercomputers from Cerebras. The first computer, Condor Galaxy 1 (CG-1), is capable of 4 quintillion floating-point operations per second (4 exaflops) of compute and contains 54 million cores. In November 2023, the second computer, the Condor Galaxy 2 (CG-2), was announced, with similar specifications as the CG-1. In March 2024, the companies broke ground on the Condor Galaxy 3 (CG-3), which can reach 8 exaFLOPs of performance and contains 58 million AI-optimized cores. In August 2023, Cerebras, the Mohamed bin Zayed University of Artificial Intelligence, and G42 subsidiary Inception launched Jais, a large language model. In March 2024, Cerebras introduced Wafer Scale Engine (WSE-3) architecture, a 5nm-based chip hosting 4 trillion transistors and 900,000 AI-optimized cores, and the basis for the CS-3. It has twice the performance of CS-2. The CS-3 was named to the list of the "best inventions of 2024" by Time.
Sources: en.wikipedia.org
PT-141 was the internal development code assigned to bremelanotide during preclinical research. Reference sources sometimes index the peptide under the code rather than the generic name. The two terms describe the same molecule.
They are related but distinct cyclic peptides. Melanotan II is an earlier and less selective melanocortin analog. Bremelanotide was developed later with a narrower receptor profile and a defined clinical application.
The reviewed product is given by subcutaneous injection using a single-use autoinjector. Administration occurs under prescription supervision. The device delivers one fixed amount per use rather than a measured or adjustable quantity.
Bremelanotide binds several melanocortin receptors, and MC4R is the subtype most often cited as responsible for its behavioural effects. Activity at MC1R, MC3R and MC5R is also reported. Selectivity is therefore described as limited rather than precise.